---
title: "uniQure/ CSL Behring&#39;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years"
date: "2025-02-08 02:04:43"
summary: "CSL and uniQure&#39;s Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/07/QURE.png"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years)
